Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

A novel small molecule inhibitor of hepatitis C virus entry.

Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ.

PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.

2.

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF.

J Hepatol. 2011 Mar;54(3):566-76. doi: 10.1016/j.jhep.2010.10.014. Epub 2010 Nov 11. Review.

3.

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

Belda O, Targett-Adams P.

Virus Res. 2012 Dec;170(1-2):1-14. doi: 10.1016/j.virusres.2012.09.007. Epub 2012 Sep 23. Review.

PMID:
23009750
4.

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

Lin C, Kwong AD, Perni RB.

Infect Disord Drug Targets. 2006 Mar;6(1):3-16. Review.

PMID:
16787300
5.

Hepatitis C virus entry: potential receptors and their biological functions.

Cocquerel L, Voisset C, Dubuisson J.

J Gen Virol. 2006 May;87(Pt 5):1075-84. Review.

PMID:
16603507
6.

Antiviral resistance and the future landscape of hepatitis C virus infection therapy.

Wyles DL.

J Infect Dis. 2013 Mar;207 Suppl 1:S33-9. doi: 10.1093/infdis/jis761. Review.

PMID:
23390303
7.

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.

Hofmann WP, Zeuzem S, Sarrazin C.

J Clin Virol. 2005 Feb;32(2):86-91. Review.

PMID:
15653410
8.
9.

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.

Lee C.

Arch Pharm Res. 2011 Sep;34(9):1403-7. doi: 10.1007/s12272-011-0921-6. Review.

PMID:
21975800
10.

[Research on hepatitis C virus entry inhibitor].

Zeng Wenting, Lu X, Wang J, Jin X, Zhu J.

Bing Du Xue Bao. 2015 Jan;31(1):97-105. Review. Chinese.

PMID:
25997338
11.

Clinical impact of hepatitis B and C virus envelope glycoproteins.

Jeulin H, Velay A, Murray J, Schvoerer E.

World J Gastroenterol. 2013 Feb 7;19(5):654-64. doi: 10.3748/wjg.v19.i5.654. Review.

12.

Hepatitis C virus entry: role of host and viral factors.

Samreen B, Khaliq S, Ashfaq UA, Khan M, Afzal N, Shahzad MA, Riaz S, Jahan S.

Infect Genet Evol. 2012 Dec;12(8):1699-709. doi: 10.1016/j.meegid.2012.07.010. Epub 2012 Aug 2. Review.

PMID:
22878095
13.

New perspectives in HCV therapy: entry inhibitors.

Donia M, Cacopardo B, Libra M, Scalia G, McCubrey JA, Nicoletti F.

Recent Pat Antiinfect Drug Discov. 2010 Nov;5(3):181-94. Review.

PMID:
20497122
14.

Entry inhibitors and future treatment of hepatitis C.

Fofana I, Jilg N, Chung RT, Baumert TF.

Antiviral Res. 2014 Apr;104:136-42. doi: 10.1016/j.antiviral.2014.02.001. Epub 2014 Feb 10. Review.

PMID:
24525381
15.

Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment.

Khaliq S, Latief N, Jahan S.

Arch Virol. 2014 Jan;159(1):1-15. doi: 10.1007/s00705-013-1780-x. Epub 2013 Jul 13. Review.

PMID:
23851652
16.

Entry inhibitors: New advances in HCV treatment.

Qian XJ, Zhu YZ, Zhao P, Qi ZT.

Emerg Microbes Infect. 2016 Jan 6;5:e3. doi: 10.1038/emi.2016.3. Review.

17.

Hepatitis C Virus entry: the early steps in the viral replication cycle.

Sabahi A.

Virol J. 2009 Jul 30;6:117. doi: 10.1186/1743-422X-6-117. Review.

18.

Functional hepatitis C virus envelope glycoproteins.

Voisset C, Dubuisson J.

Biol Cell. 2004 Aug;96(6):413-20. Review.

PMID:
15325070
19.

Hepatitis C virus: virology and life cycle.

Kim CW, Chang KM.

Clin Mol Hepatol. 2013 Mar;19(1):17-25. doi: 10.3350/cmh.2013.19.1.17. Epub 2013 Mar 25. Review.

20.

Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection.

Habersetzer F, Leboeuf C, Doffoƫl M, Zeisel MB, Baumert TF.

Expert Opin Investig Drugs. 2013 Jul;22(7):853-62. doi: 10.1517/13543784.2013.794218. Epub 2013 May 2. Review.

PMID:
23634817

Supplemental Content

Support Center